Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab vs placebo as adjuvant therapy in high-risk renal cell carcinoma
CTR20170599Phase 3Completed
- Sponsor
- Roche
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in renal cell carcinoma (RCC), sponsored by Roche. Started May 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20170599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170599.